Context Therapeutics Inc.

CNTX Nasdaq SEC CIK 1842952
Follow Context Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$7.6M +21.4% vs same quarter last year
EPS, diluted −$0.08 +20% vs same quarter last year
Operating cash flow −$6.6M −0% vs same quarter last year
Operating income −$8M +25% vs same quarter last year
Net income by quarter
−$3.3M
−$4.6M
−$8.8M
−$9.7M
−$13M
−$8.7M
−$14.6M
−$7.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$36.1M
FY24−$26.7M
FY23−$24M
FY22−$14.8M
FY21−$10.5M
FY20-
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$26.4M
FY24−$14.6M
FY23−$21M
FY22−$13.6M
FY21−$8.8M
FY20-
FY19-